In our study, a statistically significant effect of local treatment Cal/BD measured by a decrease in the immunofluorescent surface area of specific TRM markers was observed only in the 12th week of therapy (CD8, CD103, CXCR6, IL-17A, IL22), and in the 4th week of treatment, only CD69 and CD4 decreased. Here, CD4 is linked to Behcet disease.